[{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ RBC Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ RBC Capital Markets"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ aTyr Pharma","highestDevelopmentStatusID":"7","companyTruncated":"aTyr Pharma \/ aTyr Pharma"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"||HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Inapplicable"}]

Find Pulmonary/Respiratory Diseases Clinical Drug Pipeline Developments & Deals by aTyr Pharma

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 06, 2025

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 22, 2024

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod), a tRNA synthetase-derived therapy, is being evaluated for pulmonary sarcoidosis, targeting a lung-enriched splice variant of HARS.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 21, 2024

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Efzofitimod is a first-in-class biologic immunomodulator, under phase 2 clinical trials for systemic sclerosis-related interstitial lung disease. It selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 31, 2023

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : aTyr intends to use the net proceeds for general corporate purposes, including the ongoing development of ATYR1923 (efzofitimod) and the expansion of its clinical development program to include a planned Phase 2 study of efzofitimod in patients with syst...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          September 02, 2023

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : RBC Capital Markets

                          Deal Size : $15.0 million

                          Deal Type : Public Offering

                          blank

                          08

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 07, 2023

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent ...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : Efzofitimod

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent ...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 19, 2023

                          Lead Product(s) : Efzofitimod,Pirfenidone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank